株式会社リボミック
Tokyo, JP · 2 known investors
Ribomic is a company with a U.S. subsidiary engaged in research and development, including pharmaceutical and research-ethics-related activities. The page describes its compliance program, ethics committee, employee training, whistleblower hotline, and management of public research funding.
Founders & leadership
YN
Yoshikazu NakamuraPresident & CEO (代表取締役社長)
Investors · 2
Competitors · 2
by search overlap
Mereo BioPharma Group3 shared keywordsMereo BioPharma is a biopharmaceutical company that develops novel therapies for rare diseases with limited or no treatment options, focusing on lead programs in osteogenesis imperfecta (OI) and Alpha-1 Antitrypsin Deficiency-associated Lung Disease (AATD-LD). It operates a capital-efficient model, acquiring high-potential therapies from pharmaceutical and biotechnology companies and advancing them through clinical development in partnership with patient communities.
Ribometrix3 shared keywords
Companies competing with 株式会社リボミック for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does 株式会社リボミック do?
- Ribomic is a company with a U.S. subsidiary engaged in research and development, including pharmaceutical and research-ethics-related activities. The page describes its compliance program, ethics committee, employee training, whistleblower hotline, and management of public research funding.
- Who are 株式会社リボミック's investors?
- 株式会社リボミック's investors include Nippon Venture Capital, SMBC Venture Capital.
- Where is 株式会社リボミック headquartered?
- 株式会社リボミック is headquartered in Tokyo, JP.